The high comorbidity burden of the hepatitis C virus infected population in the United States.
The high comorbidity burden of the hepatitis C virus infected population in the United States.
复制标题
DOI：
10.1186/1471-2334-12-86
复制
发表时间：
2012-04-11
影响因子：
3.7
通讯作者：
Pimenta JM
中科院分区：
文献类型：
--
作者：
Louie KS;St Laurent S;Forssen UM;Mundy LM;Pimenta JM
慢性丙型肝炎（HCV）疾病可并发可能影响治疗资格和结果的共病。该研究的目的是系统地回顾HCV感染人群的合并症和症状，特别是评估与HCV抗病毒治疗和疾病相关的合并症，以及比较HCV感染和未感染对照人群之间的合并症。这是一项在美国医疗索赔数据库中对慢性HCV患者进行的回顾性队列研究，旨在估计两年期间合并症的患病率。包括具有两个HCV诊断代码，连续24个月的健康保险覆盖以及完整的医疗和药房福利的患者。在7411例慢性HCV患者队列中，在研究期间几乎所有患者（> 99%）中均观察到至少一种共病状况。HCV感染患者报告的合并症数量几乎是未感染对照组的两倍。在25种最常见的合并症中，已知大多数合并症（n = 22）与HCV抗病毒治疗或疾病相关。5种最常见的合并症为肝病[其他]（37.5%）、结缔组织病（37.5%）、腹痛（36.1%）、上呼吸道感染（35.6%）和下呼吸道疾病（33.7%）。与抗病毒治疗或疾病无关的三种值得注意的合并症是良性肿瘤（24.3%）、泌尿生殖系统症状和不明确的疾病（14.8%）和病毒感染（13.8%）。该美国医疗保险HCV人群是高度共病的。有效的策略来管理这些合并症是必要的，以允许更广泛地获得HCV治疗，并减少未来的负担HCV疾病及其表现。
Chronic hepatitis C (HCV) disease can be complicated with comorbid conditions that may impact treatment eligibility and outcomes. The aim of the study was to systematically review comorbidities and symptoms in an HCV infected population, specifically assessing comorbidities associated with HCV anti-viral treatment and disease, as well as comparing comorbidities between an HCV infected and uninfected control population. This was a retrospective cohort study within a United States medical claims database among patients with chronic HCV designed to estimate the two-year period prevalence of comorbidities. Patients with two HCV diagnosis codes, 24 months of continuous health insurance coverage, and full medical and pharmacy benefits were included. Among a chronic HCV cohort of 7411 patients, at least one comorbid condition was seen in almost all patients (> 99%) during the study period. HCV-infected patients reported almost double the number of comorbidities compared to uninfected controls. Of the 25 most common comorbidities, the majority of the comorbidities (n = 22) were known to be associated with either HCV antiviral treatment or disease. The five most frequent comorbidities were liver disease [other] (37.5%), connective tissue disease (37.5%), abdominal pain (36.1%), upper respiratory infections (35.6%), and lower respiratory disease (33.7%). Three notable comorbidities not known to be associated with antiviral treatment or disease were benign neoplasms (24.3%), genitourinary symptoms & ill-defined conditions (14.8%), and viral infections (13.8%). This US medically insured HCV population is highly comorbid. Effective strategies to manage these comorbidities are necessary to allow wider access to HCV treatment and reduce the future burden of HCV disease and its manifestations.
登录
查看更多内容
影响因子：
13.5
作者：
Ghany, Marc G.;Nelson, David R.;Strader, Doris B.;Thomas, David L.;Seeff, Leonard B.
通讯作者：
Seeff, Leonard B.
影响因子：
25.7
作者：
Massard, J;Ratziu, V;Poynard, T
通讯作者：
Poynard, T
影响因子：
13.5
作者：
El-Serag, HB;Hampel, H;Rabeneck, L
通讯作者：
Rabeneck, L
影响因子：
13.5
作者：
Fried, MW
通讯作者：
Fried, MW
影响因子：
4.5
作者：
Parrilli, G.;Manguso, F.;Marchesini, G.
通讯作者：
Marchesini, G.